Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous inoculation of allogeneic gene‑modified tumor cells ACHN‑IL2 mixed with autologous tumor cells CT‑AUT in metastatic renal carcinoma
2006-001504-37Phase 3Terminated
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- Jun 2006
- Modality
- Cell Therapies, Gene Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of ACHN-IL2 and CT-AUT in metastatic renal cell carcinoma (mRCC), sponsored by Sant'Orsola-Malpighi University Hospital. Primary endpoint: Overall survival. Started Jun 2006; status: terminated.
02
Drugs
ACHN-IL2CT-AUT
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2006-001504-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001504-37.